ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0522

Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status

Xenofon Baraliakos1, Désirée van der Heijde2, Pedro Machado3, Victoria Navarro-Compán4, Lianne Gensler5, Patricia Pertel6, Erhard Quebe-Fehling6, Aimee Readie7, Hanno Richards6 and Denis Poddubnyy8, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, 4Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 5University of California San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, CA, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, Immunology, East Hanover, NJ, 8Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany

Meeting: ACR Convergence 2023

Keywords: Biologicals, C-reactive protein (CRP), spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: SURPASS, a phase 3b randomized controlled study in patients with radiographic axial spondyloarthritis (r-axSpA), found low spinal radiographic progression over 2 years with no significant difference between the secukinumab (SEC) and adalimumab biosimilar (SDZ- ADL) treatment arms.1,2 Baseline (BSL) radiographic damage (presence of syndesmophytes) and elevated C-reactive protein (CRP) levels have been identified as predictors of radiographic progression in r-axSpA.3 This study evaluated the effect of SEC and SDZ-ADL on spinal radiographic progression in subgroups of patients based on the presence of syndesmophytes and elevated high-sensitivity CRP (hsCRP) levels at BSL, from the SURPASS study.

Methods: Biologic-naïve patients with active r-axSpA and with hsCRP ≥5 mg/L and/or ≥1 syndesmophyte(s) on spinal radiographs were randomized (1:1:1) to SEC (150 or 300 mg; dose-blinded) or SDZ-ADL (40 mg; open label). Patients were categorized into the following subgroups at BSL: hsCRP ≥5 mg/L (CRP+), hsCRP < 5 mg/L (CRP−), presence of syndesmophyte(s) (Synd+), absence of syndesmophyte(s) (Synd−), and CRP+Synd+. The proportion of patients with no radiographic progression (change from BSL in modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS] ≤0.5), mean change from BSL in mSASSS, and proportion of patients with no new syndesmophytes(s) in each subgroup at week 104 (all as observed) are reported.

Results: Of the 859 patients, 653 (76%) were CRP+, 627 (73%) were Synd+, and 466 (54%) were CRP+Synd+ at BSL. Demographic and BSL disease characteristics were largely balanced across subgroups and treatment arms, except for the Synd− group in which mean age, proportion of male patients, and mean time since diagnosis were lower than in other subgroups (Table 1). All radiographic outcomes at week 104 were similar across treatment arms; however, differences were observed between subgroups irrespective of the treatment arm. The Synd− subgroup followed by the CRP− subgroup showed the least progression in all radiographic outcomes (as indicated by the higher proportion of patients with no radiographic progression and no new syndesmophytes, and lower mean change from BSL in mSASSS), across treatment arms (Figure 1). The CRP+Synd+ subgroup followed by the Synd+ subgroup and the CRP+ subgroup had higher radiographic progression compared with the Synd− and CRP− subgroups (Figure 1).

Conclusion: Spinal radiographic progression over 2 years was low with no notable difference between SEC and SDZ-ADL arms regardless of the presence or absence of specific predictive factors for progression (syndesmophytes/elevated CRP). Expectedly, patients from subgroups without predictive factors (especially Synd−, followed by CRP−) had lowest rates of radiographic progression. The presence of syndesmophytes is a stronger predictor than the presence of an elevated CRP.

References:

  1. Baraliakos X, et al. Clin Drug Investig. 2020;40(3):269-78
  2. Baraliakos X, et al. Arthritis Rheumatol. 2022;74 (suppl 9)
  3. Poddubnyy D, et al. Arthritis Rheum. 2012;64(5):1388-98

Supporting image 1

Table 1. Demographic and baseline disease characteristics by subgroup

Supporting image 2

Figure 1. Radiographic outcomes at week 104 by subgroup: A) Patients with no radiographic progression (change in mSASSS ≤0.5), B) Mean change from BSL in mSASSS, C) Patients with no new syndesmophytes


Disclosures: X. Baraliakos: AbbVie, 2, 6, BMS, 2, 6, Chugai, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer Inc, 2, 6, UCB, 2, 6; D. van der Heijde: AbbVie, 2, Bayer, 2, BMS, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, GSK, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB Pharma, 2; P. Machado: AbbVie/Abbott, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Celgene, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 6, Novartis, 2, 6, Orphazyme, 2, 6, Pfizer, 2, 6, Roche, 2, 6, UCB, 2, 6; V. Navarro-Compán: AbbVie, 2, 5, 6, Eli Lilly, 2, 6, Galapagos, 2, Janssen, 6, MoonLake, 2, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, UCB, 2, 6; L. Gensler: AbbVie, 2, Acelyrin, 2, Eli Lilly, 2, Fresenius Kabi, 2, Janssen, 2, Novartis, 2, 5, Pfizer, 2, UCB Pharma, 2, 5; P. Pertel: Bayer Consumer Health, 3, Novartis, 3; E. Quebe-Fehling: Novartis, 3, 11; A. Readie: Novartis, 3, 11; H. Richards: Novartis, 3, 11; D. Poddubnyy: AbbVie, 2, 5, 6, Biocad, 2, BMS, 6, Eli Lilly, 2, 5, 6, Gilead, 2, GSK, 2, MoonLake, 2, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Samsung Bioepis, 2, UCB Pharma, 2, 6.

To cite this abstract in AMA style:

Baraliakos X, van der Heijde D, Machado P, Navarro-Compán V, Gensler L, Pertel P, Quebe-Fehling E, Readie A, Richards H, Poddubnyy D. Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/effect-of-secukinumab-versus-adalimumab-biosimilar-on-radiographic-progression-in-patients-with-radiographic-axial-spondyloarthritis-results-from-subgroup-analyses-by-baseline-syndesmophytes-and-c-re/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-secukinumab-versus-adalimumab-biosimilar-on-radiographic-progression-in-patients-with-radiographic-axial-spondyloarthritis-results-from-subgroup-analyses-by-baseline-syndesmophytes-and-c-re/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology